The expression of LRRN4 was correlated with the progression and prognosis of colon adenocarcinoma (COAD) patients.

Yuxian Zhang,Jianlan Xie,Shengtao Zhu,Shutian Zhang,Diangang Liu

doi:10.1590/1678-4685-gmb-2021-0138

Abstract

Our present study aims to investigate the value of LRRN4 in the progression and prognosis of COAD patients. All COAD and adjacent sample data was downloaded from TCGA database. Survival analysis was performed according to Kaplan-Meier method. The real-time quantitative PCR and immunohistochemistry analysis were conducted for validation in cell lines and tissues. The GSEA was conducted to find functional KEGG pathways. Multivariate Cox regression proportional hazard mode was used to determine whether LRRN4 expression was an independent prognostic factor. The LRRN4 expression in COAD samples were significantly higher than that in adjacent samples, which was consistent with our experiments in cell lines and tissues. Along with the increase of TNM Stage, LRRN4 expression had an increasing tendency. The COAD patients with high LRRN4 expression showed undesirable prognoses. Additionally, the TGF-β signaling pathway, WNT signaling pathway and other 25 pathways were significantly activated in the high LRRN4 expression group. In conclusion, high LRRN4 expression was closely related to the onset of COAD and it was a poor prognostic factor for COAD patients.

Highlights

Colon adenocarcinoma (COAD), is the dominant type of colon cancer (Mutch, 2007), which is one of the most common gastrointestinal tumors around the world (Arnold et al, 2017)
High LRRN4 expression was closely associated with the occurrence of COAD
The results showed that the expression of LRRN4 in COAD samples (N = 41) was significantly higher than that in paired adjacent samples (P = 6e-06) (Figure 1A)

Summary

Introduction

Colon adenocarcinoma (COAD), is the dominant type of colon cancer (Mutch, 2007), which is one of the most common gastrointestinal tumors around the world (Arnold et al, 2017). COAD is a highly invasive adenocarcinoma and has great heterogeneity (Kalyan et al, 2018; Sun et al, 2016;Yang et al, 2019), which brings great challenges to the early diagnosis and treatment of COAD patients. The early detection of colon cancer would help improve overall survival after comparing the patients diagnosed at different stages (Lee et al, 2020). The progression of COAD is usually a multi‐ stage process (Mutch, 2007), which reminds both COAD patients and researchers that it is important to take actions to prevent and diagnose early. With the development of medical technology, possible biomarkers identification is a promising tool for COAD diagnosis and prognosis. More specific biomarkers of COAD are still urgently needed

Methods

Results

Conclusion